Previous 10 | Next 10 |
home / stock / ucbjf / ucbjf news
Summary argenx pre-announced strong Q4 net sales of Vyvgart in early January. The PDUFA date for subcutaneous efgartigimod was pushed back by three months, which means the $98 million Priority Review voucher went to waste. Getting subcutaneous efgartigimod to market is important as ...
Summary Immunovant is developing a similar drug to argenx, but at 10% of argenx’s valuation, offering a good option value and a hedge against owning argenx. Immunovant has a new generation anti-FcRn IMVT-1402, and recent pre-clinical data showed that it does not impact albumin le...
UCB ( OTCPK:UCBJF ) said phase 3 data from three trials on its monoclonal antibody bimekizumab indicate its effectiveness for psoriatic arthritis, non-radiographic axial spondyloarthritis, and ankylosing spondylitis. Data from one trial showed that treatment with bime...
The U.S. Food and Drug Administration approved UCB's (OTCPK:UCBJF) (OTCPK:UCBJY) Fintepla (fenfluramine) oral solution CIV to treat seizures associated with Lennox-Gastaut syndrome (LGS) in patients two years of age and older. The FDA has also granted Fintepla pediatric exclusi...
The following slide deck was published by UCB SA in conjunction with their 2021 Q4 earnings call. For further details see: UCB SA 2021 Q4 - Results - Earnings Call Presentation
UCB SA (UCBJF) Q4 2021 Earnings Conference Call February 24, 2022, 8:00 AM ET Company Participants Jean-Christophe Tellier – Chief Executive Officer Sandrine Dufour – Chief Financial Officer Iris Löw-Friedrich – Chief Medical Officer Antje Witte – Vice Preside...
UCB SA press release (OTCPK:UCBJF): FY Non-GAAP EPS of €6.49. Revenue of €5.78B (+8.0% Y/Y). For further details see: UCB SA Non-GAAP EPS of €6.49, revenue of €5.78B
GlaxoSmithKline (GSK +1.7%) has joined a long list of pharmaceutical companies that will limit its medications purchased at prices under the federal government's 340B drug discount program to certain safety net hospital covered entities. In a letter sent Monday, GSK (GSK +1.7%) said that begi...
Zogenix (NASDAQ: ZGNX) stock is having the ride of its life this week -- perhaps for the last time in its history. The biotech announced Wednesday it agreed to be acquired by Belgium-based pharmaceutical company UCB (OTC: UCBJF) . The deal is valued at up to $1.9 billion whe...
UCB SA (UCBJF) Q2 2021 Results Conference Call July 29, 2021 08:00 AM ET Company Participants Antje Witte - VP, IR Jean-Christophe Tellier - CEO Emmanuel Caeymaex - EVP, Head, Immunology Patient Value Unit Iris Löw-Friedrich - Chief Medical Officer Sandrine Dufour - CFO Charl Van Zyl - E...
News, Short Squeeze, Breakout and More Instantly...
Ucb Sa Npv Company Name:
UCBJF Stock Symbol:
OTCMKTS Market:
SunPower Corporation (SPWR) is expected to report $-0.29 for Q1 2024 Siemens Healthineers AG ADR (SMMNY) is expected to report for Q2 2024 Specificity Inc Com (SPTY) is expected to report for Q1 2024 Tokyo Gas Co. Ltd. ADR (TKGSY) is expected to report for Q4 2024 Gol Linhas Aerea...
Yoshiharu Global Co. (YOSH) is expected to report for Q1 2024 Analog Devices Inc. (ADI) is expected to report $1.26 for Q2 2024 Simplicity Esports (WINR) is expected to report for Q3 2024 Klepierre (KLPEF) is expected to report for Q1 2024 Synopsys Inc. (SNPS) is expected to repor...
SilverBow Resorces Inc. (SBOW) is expected to report $2.36 for Q4 2023 FAT Brands Inc. Class B Common Stock (FATBB) is expected to report for quarter end 2023-12-31 Ecovyst Inc. (ECVT) is expected to report $0.2 for Q4 2023 MYR Group Inc. (MYRG) is expected to report $1.41 for Q4 2023...